This paper is in the following e-collection/theme issue:
RCTs - Protocols/Proposals (non-eHealth) (296)Published on in Vol 5, No 4 (2016): Oct-Dec
![A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS) A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)](https://asset.jmir.pub/assets/2879487ac7a384b6a880c95cb11b5fdf.png 480w,https://asset.jmir.pub/assets/2879487ac7a384b6a880c95cb11b5fdf.png 960w,https://asset.jmir.pub/assets/2879487ac7a384b6a880c95cb11b5fdf.png 1920w,https://asset.jmir.pub/assets/2879487ac7a384b6a880c95cb11b5fdf.png 2500w)
A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)
A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)
Authors of this article:
Nobuko Yamaguchi1![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
![Author Orcid Image](https://asset.jmir.pub/assets/static/images/Orcid-ID-Logo-Colour.png)
There are currently no tweets available for this article within the specified range.